Satellos Bioscience Inc.

Satellos Bioscience Inc. is a clinical-stage biotechnology and drug development company based in Toronto, Canada, focused on developing novel small molecule therapeutics to restore natural muscle repair and regeneration in degenerative muscle diseases. The company's core scientific approach targets the underlying defect in muscle repair, specifically addressing the impairment of muscle stem cell polarity and regenerative capacity, rather than solely protecting existing muscle. Satellos' lead drug candidate is SAT-3247, described as a first-of-its-kind, orally administered small molecule drug. SAT-3247 is designed to address deficits in muscle repair and regeneration by targeting AAK1, a key protein identified by Satellos as capable of helping restore muscle stem cell signaling disrupted in Duchenne muscular dystrophy (DMD). The company is currently evaluating SAT-3247 in the BASECAMP Phase 2 placebo-controlled clinical trial for boys aged 7 to less than 10 years living with DMD. Beyond SAT-3247, Satellos leverages its proprietary discovery platform called MyoReGenX™. This platform is utilized to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may offer therapeutic benefits and represent future clinical development opportunities. Satellos aims to develop life-improving medicines for conditions such as Duchenne muscular dystrophy, with the goal of rebuilding muscle. Sources: [1] https://www.stocktitan.net/overview/MSCLF/ [2] https://pitchbook.com/profiles/company/265732-30 [3] https://www.bitget.com/stock/tsx-mscl/what-is [4] https://www.listingtrack.io/company/16085 [5] https://www.crystalra.com/hubfs/SATELLOS_Executive-Informational-Overview_10-05-23.pdf [6] https://www.drugdiscoverynews.com/organization/satellos-bioscience-inc [7] https://seekingalpha.com/article/4818495-satellos-bioscience-promising-novel-treatment-for-duchenne-muscular-dystrophy [8] https://www.massbio.org/members/satellos-bioscience/ [9] https://www.perplexity.ai/finance/MSCLF [10] https://www.barchart.com/stocks/quotes/MSCLF